Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case Report

No intrauterine vertical transmission in pregnancy with COVID-19: A case report

Yantian Lv a,1, Binbin Gu b,1, Ying Chen a, Siming Hu a, Ting Ruan a, Guopeng Xu a, Jian Ding b, Xiao Xu a,*, Xinghua Shen b,**

a Department of Respiratory and Critical Medicine, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
b Department of Intensive Care Unit, The Fifth People’s Hospital of Suzhou, Infectious Disease Hospital Affiliated to Soochow University, Suzhou, China

Article info

Article history:
Received 10 June 2020
Received in revised form 18 July 2020
Accepted 28 July 2020
Available online 5 August 2020

Keywords:
SARS-COV-2
Intrauterine vertical transmission
COVID-19
Pregnancy
Prognosis

Abstract

The coronavirus disease 2019 (COVID-19) has been a worldwide pandemic disease, nearly 400,000 people died at now. The data of status of pregnant women and neonates after infection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is limited. We report a case of pregnant woman in her third trimester with critical COVID-19, and amniotic fluid, umbilical cord blood, placenta, and neonatal gastric fluid were retained during cesarean section. The SARS-COV-2 nucleic acid test results of these specimens were negative. There is no evidence of intrauterine vertical transmission during delivery in the third trimester, but the data are limited and need to be further explored.

© 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Since the SARS-COV-2 virus was discovered in China in December 2019, as of June 05, 2020, WHO confirmed 6,535,354 cases of (SARS-COV-2) infections worldwide, and nearly 400,000 deaths were declared [1]. As a special population, pregnant women have attracted much attention, and the presence of intrauterine vertical transmission is critical to the outcome of newborns. Here, we report a pregnant woman with critical COVID-19 to provide some help for the treatment of pregnant women.

2. Case report

A 28-year-old 31-week pregnant woman was admitted to the Fifth People’s Hospital of Suzhou on February 6, 2020 for recurrent fever and cough in 2 weeks. Epidemiological history showed that the patient went to Wuhan to visit relatives on January 4, and returned to Suzhou on January 23. She developed fever on January 25, with a maximum body temperature of 38.3 °C. She went to the fever clinic of Suzhou Municipal Hospital on February 2. The blood test showed a normal white blood cells, lymphopenia and elevated CRP (Table 1). The result of the SARS-COV-2 nucleic acid test was negative, however, given her epidemiological history, the possibility of SARS-COV-2 infection remained to be considered. A chest CT scan on February 4 revealed multiple peripheral ground-glass exudates with partial consolidation in bilateral lungs (Fig. 1). On February 6, after the 4th SARS-COV-2 nucleic acid test returned to be positive, she was transferred to the Fifth People’s Hospital of Suzhou for treatment.

Blood test showed 10.60 × 10^9/L of WBC, 0.85 × 10^9/L of lymphocytes, 124.1mg/L of CRP, 0.288 ng/ml of PCT. ABG analysis showed that PO2 was 120.6 mmHg, PCO2 was 38.2 mmHg, and PO2/FiO2 index was 294. According to the SARS-COV-2 pneumonia protocol (5th edn) [2], the pregnant woman was classified as critical type of COVID-19. We gave her high flow oxygen, Lopinavir/Ritonavir for antiviral, cefoperazone Tazobactam for anti-infection, dexamethasone for fetal maturation, and symptomatic management.

On February 8, the fetal heart rate was 100 beats/min, the patient’s ABG analysis showed that PF index was 208, and CT scan indicated pulmonary lesions deteriorated. The cesarean section was performed under lumbosacral combined anesthesia immediately, and a 1830g
live-born male infant was delivered successfully. Amniotic fluid, umbilical cord blood, placenta, and neonatal gastric fluid were collected during the operation and tested for the SARS-COV-2 nucleic acid, and the mother and infant were separated after the operation.

On February 9, a blood test showed an increase in PCT of 1.63 ng/ml, linezolid was added to enhance anti-infection. Lopinaviri/Ritonavir was replaced by abidol because of nausea and vomiting. On February 12, CT scan indicated that the lesions absorbed than before and her clinical symptoms improved continually. On February 18, chest CT showed that the lesions almost disappeared. In addition, the sputum SARS-COV-2 nucleic acid test was negative for the fourth time, and the anal swab SARS-COV-2 nucleic acid was also negative. The patient was discharged on February 20.

As for the newborn, his Apgar scores were 8, 8 and 10 at 1, 5, and 10 minutes after birth, with weight of 1830g, blood pressure of 77/48 mmHg, and pulse oxygen 95%. He was admitted to the negative pressure isolation ward after birth, NCPAP breathing support, given sulbenicillin sodium, azithromycin for anti-infection treatment. In addition, not only SARS-COV-2 nucleic acid test results were negative in 4 times pharyngeal swabs, but also the anal swab, amniotic fluid, umbilical cord blood, placenta, and neonatal gastric fluid were negative. On March 28, the neonatal weight had grown to 2530g, with no difficulties of breathing and pulse oxygen of 99%, he was discharged.

### 3. Discussion

The common syndrome of COVID-19 are fever, dry cough, sore throat, muscle soreness, shortness of breath, occasional diarrhea and other symptoms [3–5]. There was no significant difference in symptoms between pregnant women and non-pregnant women [6]. It should be noted that this case was diagnosed based on multiple nucleic acid tests. For nucleic acid testing, sputum specimens are recommended because the positive rate of sputum (74.4%–88.9%) is higher than that of the nasopharynx swap (53.6%–73.3%) [7]. In treatment, Lopinavir/Ritonavir has been shown to be safe in HIV-infected pregnant women, but due to adverse reactions, we used arbidol instead, which was proven to be safe and effective.

Another important question is whether there is a possibility of intrauterine vertical transmission. Chen [6] reported the delivery of 9 cases of pregnant women with COVID-19. SARS-CoV-2 tests were performed on amniotic fluid, umbilical cord blood, neonatal throat swabs and breast milk samples from six of these patients. The results were negative. Zhu [8] described 10 neonates in pregnant women with COVID-9, including two cases of vaginal delivery. 9 cases had pharyngeal swab specimens taken 1–9 days after birth for SARS-CoV-2 nucleic acid tests, all of which were negative. Li [9] also reported a 35-week pregnant woman with COVID-19, whose

---

### Table 1

Clinical, laboratory characteristics and medicine of a pregnant woman with COVID-19.

| Date | WBC (× 10^9/L) | LYM (× 10^9/L) | PT (s) | D-dimer (mg/L) | N-proBNP (pg/ml) | cTn (ng/ml) | AST (U/L) | Cre (μmol/L) | CRP (mg/L) | PCT (ng/ml) | PF index Medicine |
|------|----------------|----------------|--------|----------------|-----------------|-------------|------------|-------------|-------------|-------------|--------------------|
| 2/2  | 8.76           | 1.06           |        |                | 24              | 39          | 60.00      | 0.03        | Ose         |            |                   |
| 2/6  | 10.60          | 0.86           | 11.70  | 0.84          | 318             | 0.02        | 33         | 25.70       | 124.10      | 0.29        | 294     Lop/Rit Cef |
| 2/8  | 8.66           | 1.06           | 11.10  | 0.99          | 162             | 0.04        | 34         | 33.80       | 47.90       | 0.20        | 208     Lop/Rit Cef, Lin |
| 2/9  | 21.41          | 1.62           | 10.90  | 2.14          | 822             | 0.02        | 34         | 33.80       | 19.06       | 1.63        | 219     Arb, Cef, Lin |
| 2/10 | 13.62          | 2.18           | 11.00  | 5.90          | 355             | 0.03        | 42         | 37.00       | 14.70       | 0.09        | 252     Arb, Cef, Lin |
| 2/11 | 13.66          | 1.61           | 11.10  | 2.01          | 92              | 0.01        | 38         | 30.90       | 43.10       | 0.07        | 303     Arb, Cef, Lin |
| 2/12 | 12.39          | 1.65           | 11.20  | 1.67          | 18              | 0.01        | 18         | 32.00       | 49.00       | 0.04        | 401     Arb, Cef, Lin |
| 2/13 | 11.12          | 1.52           | 11.30  | 2.14          | 54              | 0.00        | 17         | 33.60       | 31.30       | 0.03        | 409     Arb, Cef, Lin |
| 2/14 | 9.78           | 1.50           | 11.40  | 2.76          | 43              | 0.00        | 17         | 31.00       | 44.80       | 0.04        | 404     Arb, Cef, Lin |
| 2/17 | 8.69           | 1.84           | 17.10  | 2.52          | 68              | 0.00        | 39         | 34.40       | 15.90       | 0.05        | 484     Arb, Cef, Lin |

**Abbreviations:** WBC: White Blood Cell; LYM: Lymphocyte; PT: Prothrombin time; cTn: Cardiac troponin; AST: Aspartate aminotransferase; Cre: Creatinine; CRP: C-reactive protein; PCT: Procalcitonin; PF index: PO2/FiO2 index; Ose: Oseltamivir; Arb: Arbidol; Lop/Rit: Lopinaviri/Ritonavir; Cef: Cefoperazone Tazobactam; Lin: Linezolid.
amniotic fluid, cord blood and placenta, breast milk samples as well as neonates swab SARS-COV-2 nucleic acid were all negative. However, Dong [10] reported a case of a neonate by cesarean, whose SARS-COV-2 IgG and IgM were positive 2 hours after birth. Before her born, her mother had been infected SARS-COV-2 for more than 20 days. It is known that IgM antibodies are not transferred to the fetus via the placenta. It seemed that the elevated IgM in the neonate indirectly supported the possibility of vertical transmission, but it still needs to be discussed because the mother's vaginal secretions were negative for SARS-COV-2, and there were no PCR testing of amniotic fluid or placenta to be performed. Also, the infant's repeatedly RT-PCR test of SARS-COV-2 results on nasopharyngeal swabs were negative. Unfortunately, due to the early stage of the SARS-COV-2 epidemic at that time, the SARS-COV-2 IgM antibody testing had not been applied in our hospital, and this newborn failed to perform IgM testing.

Placental pathology are of great significance for understanding maternal and fetal outcomes and evaluating intrauterine vertical transmission. Chen [11] analyzed 3 cases of placental pathology of SARS-COV-2 infection in pregnancy, they found that there were various degrees of fibrin deposition inside and around the villi with local syncytial nodule increases in all three placentas, but no morphological changes of villitis and choriamnionitis related to infection of SARS-COV-2 were observed. Unfortunately, this maternal placenta was treated as a potential contaminant and failed to undergo a pathological examination. Based on these results, although clinical samples are small, there is no direct evidence of intrauterine vertical transmission. However, these pregnant women are all in the third trimester. It is uncertain whether there is vertical intrauterine transmission during delivery of COVID-19 pregnant women in the first and second trimester.

Smith V et al. reviewed outcomes of maternal and neonatal in pregnant women with COVID-19 from November 1st, 2019 to March 28th, 2020. There was no indeterminate case of potential vertical transmission, and the proportion of critically ill pregnant women was small [12]. But pregnant women infected with SARS and MERS can easily progress to critical illness with a mortality rate of about 30% [13,14]. Miscarriage, preterm birth, intrauterine distress were common in these women, and most newborns needed to be admitted to ICU. On February 29, 2020, the China-World Health Organization (WHO) Joint Investigation Report on New Coronavirus Pneumonia (COVID-19) was published, and 147 pregnant women were analyzed, of whom 8% were severe and 1% were critical [15]. It seems that the risk of pregnant women with COVID-19 progressing to severe patients is not high, but this still needs further observation.

In a word, pregnant women are a special group in the SARS-COV-2 epidemic. They should be paid more attention because of the safety of pregnant women and their fetuses. In view of the current SARS-COV-2 epidemic in the world, pregnant women with flu symptoms should be tested for SARS-COV-2 nucleic acid as soon as possible, combined with IgM antibody testing if necessary. As of now, there is no sufficient evidence of intrauterine vertical transmission during delivery in the third trimester, but the data are limited and need to be further explored. Newborns are still advised to be separated from the mother, stopped breastfeeding, and observed for manifestations to rule out SARS-COV-2 infection.

Authorship statement

Yantian Lv and Xiao Xu were responsible for the organization and coordination of the clinical case. Xinghua Shen was the chief investigator and responsible for the data analysis. Yantian Lv, Binbin Gu, Siming Hu, Ying Chen, Ting Ruan, Jian Ding and Guoping Xu collected clinical data. All authors contributed to the writing of the final manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors meet the ICMJE authorship criteria.

Ethics approval

Informed consent was obtained from the patient for publication of this case report. No potentially identifiable human images or data is presented in this study. The studies involving human participants were reviewed and approved by Ethics Committee of Suzhou Municipal Hospital.

Funding

This study was supported by grants from Tackling of key scientific and emergency special program of 2019-nCoV infection of Suzhou Municipal Science and Technology Bureau (SYS2020038).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

References

[1] WHO. Novel coronavirus (SARS-COV-2). Situation report-1. https://www.who.int/docs/default-source/sri-lanka-documents/20200605-covid-19-sitrep-137.pdf?sfvrsn=a13df572_2; June 05, 2020.
[2] National Health Commission of China. New coronavirus pneumonia prevention and control program (5th edn). http://www.nhc.gov.cn/yzygj/s7653p/202002/ d4b953j37e19445b8d728caffe3e13a/files/abebce793164c7998ed8091203cd6.pdf; [Accessed 1 March 2020] [in Chinese].
[3] Wang Dawei, Hu Bo, Hu Chang, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus--infected pneumonia in wuhan, China. JAMA 2020 Feb 7;323(11):1061–9.
[4] Nanshan Chen, Min Zhou, Xuan Dong, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395(10223), 507-513.
[5] Henry Brandon M., Vikse Jens. Clinical characteristics of covid-19 in N. Engl J Med, 382(19), 1860-1861.
[6] Chen H, Gao J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records | Lancet, 395(10226), 809-815.
[7] Yang Yang, Minghua Yang, Chengxu Shen, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infection. medRxiv preprint doi: org/10.1101/ 2020.02.11.20021459.
[8] Zhu Huaping, Wang Lin, Fang Chengzhi, Peng Sichong, Zhang Lianhong, Chang Guiping, Xia Shiwen, Zhou Wenhao. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia, Transl Pediatr, 9(1), 51-60.
[9] Li Y, Zhao R, Zheng S, et al. Lack of vertical transmission of severe acute respiratory syndrome coronavirus 2, China. Emerg Infect Dis, 26(6), 1335-1336.
[10] Lan Dong, Tian Jinhua, He Songming, et al. Possible vertical transmission of SARS-COV-2 from an infected mother to her newborn. J Am Med Assoc 2020;323(14):1846–8.
[11] Chen shuo, Huang Bo, Luo Danju, et al. Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases, Chin J Pathol 2020;49, E005-E005.
[12] Smith Vinayak, Seo Densearn, Ritesh Warty, et al. Maternal and neonatal outcomes associated with COVID-19 infection: a systematic review. PloS One 2020;15:e0234187.
[13] Schwartz David A, Ashley L, et al. Potential maternal and infant outcomes from (wuhan) coronavirus 2019-nCoV infected pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses 2020;12(2):194. https://doi.org/10.3390/v12020194.
[14] de Wit Emmie, van Doremalen Neeltje, Falzarano Darryl, Munster Vincent J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol, 14(8), 523-534.
[15] The China-World Health Organization (WHO) Joint Investigation Report on New Coronavirus Pneumonia(COVID-19). http://www.nhc.gov.cn/jkj/s3578/ 202002/8767025108964494baae5b689f5c8/files/ e73a238d8eff45d5ab8b55a078464cdd.pdf.